NeOnc Technologies (NTHI) said Tuesday that its phase 1 trial of NEO212 for the treatment of brain cancer is nearing full enrollment.
The final group is expected to complete the study's dosing protocol, the company said, adding that the NEO212 trial protocol has five escalating groups with three patients per group.
NEO212 is a combination of temozolomide, which is the current standard-of-care chemotherapy for malignant gliomas, and perillyl alcohol, NeOnc said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。